HeartBeam to Discuss Q3 2025 Results and Regulatory Progress in November Conference Call

HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold a conference call on Thursday, November 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended September 30, 2025. The Company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A detailed press release will be issued prior to the call, with the full announcement available at https://ibn.fm/5mXsb.

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management.

The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review. HeartBeam holds over 20 issued patents related to technology enablement, positioning the company at the forefront of portable cardiac monitoring innovation. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.

This development matters because it represents a significant advancement in cardiac care technology that could enable earlier detection and monitoring of heart conditions outside traditional medical settings. The ability to capture comprehensive 3D ECG data through portable devices has the potential to improve patient outcomes by allowing for more frequent monitoring and earlier intervention. The regulatory progress and commercial readiness updates to be discussed during the conference call will provide important insights into the company's path to market and potential impact on cardiac care delivery.

The technology's implications extend beyond clinical applications to potentially reduce healthcare costs by minimizing unnecessary hospital visits and enabling more efficient remote patient monitoring. As cardiovascular diseases remain a leading cause of mortality worldwide, innovations like HeartBeam's 3D ECG platform could play a crucial role in improving access to cardiac care and enabling more proactive management of heart health. The upcoming conference call will offer stakeholders important information about the company's progress in bringing this transformative technology to patients and healthcare providers.